Proteomics International Laboratories Ltd - Asset Resilience Ratio
Proteomics International Laboratories Ltd (PIQ) has an Asset Resilience Ratio of 57.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Proteomics International Laboratories Lt (PIQ) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Proteomics International Laboratories Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Proteomics International Laboratories Lt's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Proteomics International Laboratories Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Proteomics International Laboratories Lt to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$6.49 Million | 57.44% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$6.49 Million | 57.44% |
Asset Resilience Insights
- Very High Liquidity: Proteomics International Laboratories Ltd maintains exceptional liquid asset reserves at 57.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Proteomics International Laboratories Ltd Industry Peers by Asset Resilience Ratio
Compare Proteomics International Laboratories Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Proteomics International Laboratories Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Proteomics International Laboratories Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 63.71% | AU$9.42 Million ≈ $6.66 Million |
AU$14.78 Million ≈ $10.46 Million |
+6.70pp |
| 2024-06-30 | 57.00% | AU$6.20 Million ≈ $4.39 Million |
AU$10.88 Million ≈ $7.69 Million |
-0.47pp |
| 2023-06-30 | 57.47% | AU$5.79 Million ≈ $4.10 Million |
AU$10.08 Million ≈ $7.13 Million |
+38.94pp |
| 2022-06-30 | 18.53% | AU$1.00 Million ≈ $707.56K |
AU$5.40 Million ≈ $3.82 Million |
-40.19pp |
| 2021-06-30 | 58.72% | AU$5.05 Million ≈ $3.57 Million |
AU$8.60 Million ≈ $6.08 Million |
+57.82pp |
| 2020-06-30 | 0.90% | AU$50.00K ≈ $35.38K |
AU$5.55 Million ≈ $3.93 Million |
-28.10pp |
| 2019-06-30 | 29.00% | AU$1.05 Million ≈ $742.94K |
AU$3.62 Million ≈ $2.56 Million |
-13.17pp |
| 2018-06-30 | 42.16% | AU$2.32 Million ≈ $1.64 Million |
AU$5.49 Million ≈ $3.89 Million |
+15.33pp |
| 2017-06-30 | 26.83% | AU$775.14K ≈ $548.46K |
AU$2.89 Million ≈ $2.04 Million |
-- |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more